Journal of Clinical Oncology
Articles in this Issue
Incidence of pneumonitis in Asian patients with small cell lung cancer: A systematic literature review and meta-analysis.
e20123 Background: Pneumonitis is a well-documented adverse event (AE) among those with lung cancer receiving immune checkpoint inhibitor or radiotherapy....
Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.
10005 Background: Osteosarcoma is the most common bone tumor of children, adolescents, and young adults and patients with...
Toward sequencing every core needle biopsy by addressing one "gap" at a time.
e23220 Background: Core needle biopsies (CNB) are essential for clinical diagnostics, therapy guidance, and enrollment in certain clinical trials. However...
Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).
e19049 Background: Liso-cel, axi-cel, and tisa-cel are FDA-approved chimeric antigen receptor T cell therapies for 3L+ R/R FL, but no head-to-head compari...
Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).
e17064 Background: Analyses of clinical trials data suggest thatBlack men have equal or even improved overall survival (OS) with certain treatments for mC...
Eliminating breast surgery for triple negative or HR-/HER2+ breast cancer patients with clinical complete response to combined neoadjuvant chemotherapy and neoadjuvant radiotherapy: A multicenter, phase 2 trial (EBCS).
TPS630 Background: Recent advancements in immunotherapy and targeted therapies have significantly improved pathological complete response (pCR) rates in p...
EXPAND-1, a phase I/II study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.
TPS2701 Background: ANV600 is a novel PD-1 targeted, interleukin-2 receptor beta/gamma (IL-2Rβ/γ) selective agonist. This bispecific agent comprises two f...
Real-world impact of breast cancer recurrence: Understanding patient and caregiver perspectives in the United States through social media analysis.
e23277 Background: There is limited published evidence on the experiences of patients and caregivers in the USA related to early breast cancer (eBC) risk...
Efficacy and safety of cadonilimab in recurrent/metastatic solid tumors including ICI-treated tumors in clinical practice: Cohorts of head and neck squamous cell carcinoma and cervical cancer.
e17502 Background: Checkpoint inhibitors (ICIs) has been approved for treating multiple solid tumors, the real-world clinical benefits are under widely di...
Treatment patterns, use of healthcare resources, and clinical characteristics of patients with castration-resistant prostate cancer (mCRPC) in Colombia: Preliminary analysis from ProColombia RC study.
11059 Background: The clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients in Colombia remain poorly understood, p...
Efficacy of temperature-controlled hand-foot cryotherapy to prevent chemotherapy-induced polyneuropathy (CIPN): 1-year follow-up of a single-center, prospective, real-world data collection.
e24074 Background: Advancements in oncology have significantly improved the overall survival of patients with cancer, particularly those with breast cance...
Germline genetic testing in patients with uterine serous carcinoma at a tertiary academic center.
e17640 Background: There is emerging evidence for germline genetic contribution to cases of uterine serous carcinoma (USC). Cohort studies of individuals...
Escalating impact of alcohol-related cancer mortality in the US: A call for action.
10519 Background: Alcohol consumption is known to be a significant risk factor for cancer. This year, the US Surgeon General recommended adding cancer ris...
LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.
3151 Background: To explore PARP inhibitor (PARPi) utility across solid tumors and identify biomarkers that predict sensitivity. Methods:...
CDK4/6 inhibitor toxicity in geriatric subgroups: Evidence from the FAERS database.
12126 Background: Despite their widespread use, the safety of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in geriatric patients remains underexplored...
Evaluating artificial intelligence (AI) as a clinical decision support tool for lung cancer treatment recommendations.
e20011 Background: The therapeutic landscape of lung cancer is rapidly evolving, presenting oncologists with the challenge of staying updated amidst an ov...
What's weight got to do with it? In-hospital outcomes in colorectal cancer patients with and without obesity: An NIS analysis.
e15667 Background: Obesity is a significant risk factor for various cancers, including colorectal cancer (CRC), the most common gastrointestinal malignanc...
PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.
5070 Background: Prostate-specific membrane antigen (PSMA) is a validated therapeutic target in mCRPC. 225Ac-J591, an alpha-emitting radionuclide linked t...
AI-augmentation of multiplex chromogenic assays for use with colocalized multi-specific targets.
e15178 Background: Assessing the co-localization of protein targets is important to aid in the selection of patients who may benefit from emerging multisp...
Primary results from IChoice-02, a phase 2 trial of induction chemoimmunotherapy followed by response-adapted de-escalation of chemoradiation in HPV-associated oropharyngeal cancer.
6071 Background: Despite multiple attempts to de-intensify treatments in HPV-associated oropharyngeal cancer (OPC), data with incorporation of immunothera...
Gynecologic oncology referral rates of adnexal masses suspicious for ovarian cancer in an academic health system: A cohort study.
5544 Background: Ovarian-Adnexal Reporting Data System (O-RADS) is an international lexicon and risk stratification tool. O-RADS 4 or 5 lesions are comple...
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer.
1105 Background: Immunotherapy has emerged as a promising treatment option for metastatic triple-negative breast cancer (mTNBC), yet the factors influenci...
Global lipidomics analysis of early- and late-stage ovarian cancer serum.
e17587 Background: Ovarian cancer (OC) is the fifth leading cause of cancer-related deaths among women. For most patients, detection occurs at late stages...
NGS technologies and metastatic colorectal cancer: Experience and future in Uzbekistan.
e15638 Background: Colorectal cancer (CRC) is a growing concern in Uzbekistan, with an incidence of 5.5 per 100,000 people in 2024. It accounts for 10% of...
Disparities and predictors of survival in non-surgical management of malignant bowel obstruction: Insights from a Southwestern US cohort.
e16470 Background: Malignant bowel obstruction (MBO) is a severe complication in advanced cancer, affecting up to 15% of patients. It is managed with anti...